ArticleCell communication and signaling : CCS2017
Impaired mitochondrial calcium uptake caused by tacrolimus underlies beta-cell failure.
Article in Cell communication and signaling : CCS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Kidney transplantation in mitochondrial diseases: a systematic review.Pediatric nephrology (Berlin, Germany) · 2026Pooled it
- Effects of Chronic Supplementation of L-Arginine on Physical Fitness in Water Polo Players.Oxidative medicine and cellular longevity · 2021Trial
- Myokines and mitochondrial function in cardiometabolic diseases.Journal of physiology and biochemistry · 2026Review
- Immunosuppression in children with primary mitochondrial diseases after kidney transplantation: insight from case series of RMND1-related disease.Pediatric nephrology (Berlin, Germany) · 2026Article
- Different Effects of Tacrolimus on Osseointegration and Bone Mass in Normal Bone Mineral Density and Ovariectomized Rats.Calcified tissue international · 2026Article
- Evaluating the Neuroprotective and Acetylcholinesterase Inhibitory Properties of Four Calcineurin Inhibitor Drugs: Tacrolimus, Pimecrolimus, Cyclosporin A, and Voclosporin.Molecular neurobiology · 2025Article
- Changes in the gut microbiota and derived fecal metabolites may play a role in tacrolimus-induced diabetes in mice.Future microbiology · 2025Article
- L-Arginine supplementation as mitochondrial therapy in diabetic cardiomyopathy.Cardiovascular diabetology · 2024Article
- Cutting edge of immune response and immunosuppressants in allogeneic and xenogeneic islet transplantation.Frontiers in immunology · 2024Review
- Reg3γ: current understanding and future therapeutic opportunities in metabolic disease.Experimental & molecular medicine · 2023Review
- Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease.iScience · 2023Article
- Review
- Editorial: The link between obesity, type 2 diabetes, and mitochondria.Frontiers in endocrinology · 2023Article
- SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients.Hypertension (Dallas, Tex. : 1979) · 2022Article
- Glycation of ryanodine receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2022Article
- ATP Secretion and Metabolism in Regulating Pancreatic Beta Cell Functions and Hepatic Glycolipid Metabolism.Frontiers in physiology · 2022Review
- Targeting age-specific changes in CD4Aging cell · 2021Article
- Frailty after lung transplantation is associated with impaired health-related quality of life and mortality.Thorax · 2020Article
- Article
- A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy.Nature cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundOne of the most common side effects of the immunosuppressive drug tacrolimus (FK506) is the increased risk of new-onset diabetes mellitus. However, the molecular mechanisms underlying this association have not been fully clarified.
methodsWe studied the effects of the therapeutic dose of tacrolimus on mitochondrial fitness in beta-cells.
resultsWe demonstrate that tacrolimus impairs glucose-stimulated insulin secretion (GSIS) in beta-cells through a previously unidentified mechanism. Indeed, tacrolimus causes a decrease in mitochondrial Ca
conclusionOur observations individuate a new fundamental mechanism responsible for the augmented incidence of diabetes following tacrolimus treatment. Indeed, this drug alters Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.